Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Endocrinol (Lausanne) ; 12: 660793, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34149616

RESUMO

Metformin is an antidiabetic drug used for the treatment of diabetes and metabolic diseases. Imbalance in the autonomic nervous system (ANS) is associated with metabolic diseases. This study aimed to test whether metformin could improve ANS function in obese rats. Obesity was induced by neonatal treatment with monosodium L-glutamate (MSG). During 21-100 days of age, MSG-rats were treated with metformin 250 mg/kg body weight/day or saline solution. Rats were euthanized to evaluate biometric and biochemical parameters. ANS electrical activity was recorded and analyzed. Metformin normalized the hypervagal response in MSG-rats. Glucose-stimulated insulin secretion in isolated pancreatic islets increased in MSG-rats, while the cholinergic response decreased. Metformin treatment normalized the cholinergic response, which involved mostly the M3 muscarinic acetylcholine receptor (M3 mAChR) in pancreatic beta-cells. Protein expression of M3 mAChRs increased in MSG-obesity rats, while metformin treatment decreased the protein expression by 25%. In conclusion, chronic metformin treatment was effective in normalizing ANS activity and alleviating obesity in MSG-rats.


Assuntos
Sistema Nervoso Autônomo/efeitos dos fármacos , Hipoglicemiantes/uso terapêutico , Metformina/uso terapêutico , Obesidade/tratamento farmacológico , Acetilcolina/farmacologia , Animais , Glucose/farmacologia , Células Secretoras de Insulina/efeitos dos fármacos , Células Secretoras de Insulina/metabolismo , Masculino , Neostigmina/farmacologia , Obesidade/induzido quimicamente , Obesidade/metabolismo , Obesidade/fisiopatologia , Ratos Wistar , Receptor Muscarínico M3/metabolismo , Glutamato de Sódio , Nervo Vago/efeitos dos fármacos , Nervo Vago/fisiologia
2.
J Physiol ; 597(15): 3905-3925, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31210356

RESUMO

KEY POINTS: Cancer growth, cell proliferation and cachexia index can be attenuated by the beneficial programming effect of moderate exercise training, especially if it begins in adolescence. Walker 256 tumour-bearing rats who started exercise training during adolescence did not revert the basal low glycaemia and insulinaemia observed before tumour cell inoculation. The moderate exercise training improved glucose tolerance and peripheral insulin sensitivity only in rats exercised early in adolescence. The chronic effects of our exercise protocol are be beneficial to prevent cancer cachexia and hold clear potential as a nonpharmacological therapy of insulin sensitization. ABSTRACT: We tested the hypothesis that moderate exercise training, performed early, starting during adolescence or later in life during adulthood, can inhibit tumour cell growth as a result of changes in biometric and metabolic markers. Male rats that were 30 and 70 days old performed a treadmill running protocol over 8 weeks for 3 days week-1 , 44 min day-1 and at 55-65% V̇O2max . After the end of training, a batch of rats was inoculated with Walker 256 carcinoma cells. At 15 days after carcinoma cell inoculation, the tumour was weighed and certain metabolic parameters were evaluated. The data demonstrated that physical performance was better in rats that started exercise training during adolescence according to the final workload and V̇O2max . Early or later moderate exercise training decreased the cachexia index, cell proliferation and tumour growth; however, the effects were more pronounced in rats that exercised during adolescence. Low glycaemia, insulinaemia and tissue insulin sensitivity was not reverted in Walker 256 tumour-bearing rats who trained during adolescence. Cancer growth can be attenuated by the beneficial programming effect of moderate exercise training, especially if it begins during adolescence. In addition, improvement in glucose-insulin homeostasis might be involved in this process.


Assuntos
Carcinoma 256 de Walker/terapia , Condicionamento Físico Animal/métodos , Animais , Caquexia/metabolismo , Caquexia/prevenção & controle , Carcinoma 256 de Walker/patologia , Carcinoma 256 de Walker/prevenção & controle , Células Cultivadas , Glucose/metabolismo , Resistência à Insulina , Masculino , Ratos , Ratos Wistar
3.
J Dev Orig Health Dis ; 10(6): 608-615, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31130151

RESUMO

Early-life chronic exposure to environmental contaminants, such as bisphenol-A, particulate matter air pollution, organophosphorus pesticides, and pharmaceutical drugs, among others, may affect central tissues, such as the hypothalamus, and peripheral tissues, such as the endocrine pancreas, causing inflammation and apoptosis with severe implications to the metabolism. The Developmental Origins of Health and Disease (DOHaD) concept articulates events in developmental phases of life, such as intrauterine, lactation, and adolescence, to later-life metabolism and health. These developmental phases are more susceptible to environmental changes, such as those caused by environmental contaminants, which may predispose individuals to obesity, metabolic syndrome, and chronic noncommunicable diseases later in life. Alterations in the epigenome are explored as an underlying mechanism to the programming effects on metabolism, as the expression of key genes related with central and peripheral metabolic functions may be altered in response to environmental disturbances. Studies show that environmental contaminants may affect gene expressions in mammals, especially when exposed to during the developmental phases of life, leading to metabolic disorders in adulthood. In this review, we discuss the current obesity epidemics, the DOHaD concept, pollutants' toxicology, environmental control, and the role of environmental contaminants in the central and peripheral programming of obesity and metabolic syndrome. Improving environmental monitoring may directly affect the quality of life of the population and help protect the future generations from metabolic diseases.


Assuntos
Exposição Ambiental/efeitos adversos , Monitoramento Ambiental/métodos , Doenças Metabólicas/diagnóstico , Doenças Metabólicas/etiologia , Obesidade/complicações , Efeitos Tardios da Exposição Pré-Natal/diagnóstico , Efeitos Tardios da Exposição Pré-Natal/etiologia , Animais , Feminino , Humanos , Gravidez
4.
Mutagenesis ; 31(4): 417-24, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26825076

RESUMO

Pioglitazone (PTZ) is an oral antidiabetic agent whose anti-cancer properties have been described recently. Since PTZ increases the production of reactive oxygen species in mammalian cells, the aim of current study was to evaluate the cytotoxic, mutagenic and recombinogenic effects of PTZ using respectively the in vitro mitotic index assay and the in vitro mammalian cell micronucleus test in human peripheral lymphocytes, and the in vivo homozygotization assay in Aspergillus nidulans, which detects the loss of heterozygosity due to somatic recombination. Although the lowest PTZ concentrations (4-36 µM) did not show any significant rise in the micronucleus production, the higher PTZ concentration (108 µM) produced a statistically higher number of micronuclei than the negative control and significantly altered the cell-proliferation kinetics, demonstrating the mutagenic and antiproliferative effects of PTZ, respectively. The recombinogenic activity of PTZ, demonstrated here for the first time, was observed at the highest tested concentration (400 µM) through the homozygotization index rates significantly different from the negative control. Taken together, our results show that PTZ is genotoxic at a concentration higher than the therapeutic plasma concentration. This PTZ genotoxicity may be a potential benefit to its previously described antitumour activity.


Assuntos
Dano ao DNA , Linfócitos/efeitos dos fármacos , Micronúcleos com Defeito Cromossômico/induzido quimicamente , PPAR gama/agonistas , Tiazolidinedionas/efeitos adversos , Aspergillus nidulans/efeitos dos fármacos , Aspergillus nidulans/genética , Células Cultivadas , DNA/efeitos dos fármacos , Humanos , Hipoglicemiantes/efeitos adversos , Hipoglicemiantes/uso terapêutico , Hipoglicemiantes/toxicidade , Perda de Heterozigosidade , Testes de Mutagenicidade , Estresse Oxidativo/efeitos dos fármacos , Pioglitazona , Tiazolidinedionas/uso terapêutico , Tiazolidinedionas/toxicidade
5.
PLoS One ; 10(3): e0120675, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25803314

RESUMO

Glibenclamide is an oral hypoglycemic drug commonly prescribed for the treatment of type 2 diabetes mellitus, whose anti-tumor activity has been recently described in several human cancer cells. The mutagenic potential of such an antidiabetic drug and its recombinogenic activity in eukaryotic cells were evaluated, the latter for the first time. The mutagenic potential of glibenclamide in therapeutically plasma (0.6 µM) and higher concentrations (10 µM, 100 µM, 240 µM and 480 µM) was assessed by the in vitro mammalian cell micronucleus test in human lymphocytes. Since the loss of heterozygosity arising from allelic recombination is an important biologically significant consequence of oxidative damage, the glibenclamide recombinogenic activity at 1 µM, 10 µM and 100 µM concentrations was evaluated by the in vivo homozygotization assay. Glibenclamide failed to alter the frequency of micronuclei between 0.6 µM and 480 µM concentrations and the cytokinesis block proliferation index between 0.6 µM and 240 µM concentrations. On the other hand, glibenclamide changed the cell-proliferation kinetics when used at 480 µM. In the homozygotization assay, the homozygotization indices for the analyzed markers were lower than 2.0 and demonstrated the lack of recombinogenic activity of glibenclamide. Data in the current study demonstrate that glibenclamide, in current experimental conditions, is devoid of significant genotoxic effects. This fact encourages further investigations on the use of this antidiabetic agent as a chemotherapeutic drug.


Assuntos
Glibureto/toxicidade , Hipoglicemiantes/toxicidade , Linfócitos/efeitos dos fármacos , Mutagênicos/toxicidade , Adulto , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Diabetes Mellitus Tipo 2/tratamento farmacológico , Humanos , Linfócitos/citologia , Linfócitos/metabolismo , Testes para Micronúcleos , Adulto Jovem
6.
Drug Chem Toxicol ; 38(3): 306-11, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25231917

RESUMO

Terbinafine is an antimycotic drug usually used against several superficial fungal infections and with a potential application in the treatment of human cancers. Since to date there are few data on the genotoxic effects of terbinafine in mammalian cells, current study evaluated the potential genotoxic of such antifungal agent in cultured human peripheral blood lymphocytes. Terbinafine was used at the peak plasma concentration (1.0 µg/ml) and in four additional concentrations higher than the human plasmatic peak (5.0 µg/ml, 25.0 µg/ml, 50.0 µg/ml and 100.0 µg/ml). Chromosomal aberrations (CA), sister chromatid exchanges (SCE), micronuclei (MN), nucleoplasmic bridges (NP) and nuclear buds (NB) were scored as genetic endpoints. In all analysis no significant differences (α = 0.05, Kruskal-Wallis test) were observed. Complementary criterion adopted to obtain the final response in cytogenetic agreed with statistical results. Therefore, results of this study showed that terbinafine neither induced CA, SCE, MN, NP and NB nor affected significantly mitotic, replication and cytokinesis-block proliferation indices in any of the tested concentrations. It may be assumed that terbinafine was not genotoxic or cytotoxic to cultured human peripheral blood lymphocytes in our experimental conditions.


Assuntos
Antifúngicos/toxicidade , Linfócitos/efeitos dos fármacos , Naftalenos/toxicidade , Adulto , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Citocinese/efeitos dos fármacos , Feminino , Humanos , Linfócitos/patologia , Masculino , Micronúcleos com Defeito Cromossômico/induzido quimicamente , Testes para Micronúcleos , Mitose/efeitos dos fármacos , Medição de Risco , Troca de Cromátide Irmã/efeitos dos fármacos , Terbinafina , Adulto Jovem
7.
Cell Physiol Biochem ; 34(6): 1920-32, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25500480

RESUMO

BACKGROUND/AIMS: The objective of the current work was to test the effect of metformin on the tumor growth in rats with metabolic syndrome. METHODS: We obtained pre-diabetic hyperinsulinemic rats by neonatal treatment with monosodium L-glutamate (MSG), which were chronically treated every day, from weaning to 100 day old, with dose of metformin (250 mg/kg body weight). After the end of metformin treatment, the control and MSG rats, treated or untreated with metformin, were grafted with Walker 256 carcinoma cells. Tumor weight was evaluated 14 days after cancer cell inoculation. The blood insulin, glucose levels and glucose-induced insulin secretion were evaluated. RESULTS: Chronic metformin treatment improved the glycemic homeostasis in pre-diabetic MSG-rats, glucose intolerance, tissue insulin resistance, hyperinsulinemia and decreased the fat tissue accretion. Meanwhile, the metformin treatment did not interfere with the glucose insulinotropic effect on isolated pancreatic islets. Chronic treatment with metformin was able to decrease the Walker 256 tumor weight by 37% in control and MSG rats. The data demonstrated that the anticancer effect of metformin is not related to its role in correcting metabolism imbalances, such as hyperinsulinemia. However, in morphological assay to apoptosis, metformin treatment increased programmed cell death. CONCLUSION: Metformin may have a direct effect on cancer growth, and it may programs the rat organism to attenuate the growth of Walker 256 carcinoma.


Assuntos
Carcinoma 256 de Walker/tratamento farmacológico , Proliferação de Células/efeitos dos fármacos , Diabetes Mellitus Experimental/tratamento farmacológico , Metformina/administração & dosagem , Neoplasias/tratamento farmacológico , Animais , Glicemia , Carcinoma 256 de Walker/metabolismo , Carcinoma 256 de Walker/patologia , Diabetes Mellitus Experimental/induzido quimicamente , Diabetes Mellitus Experimental/patologia , Intolerância à Glucose/tratamento farmacológico , Intolerância à Glucose/patologia , Hipoglicemiantes/administração & dosagem , Insulina/metabolismo , Resistência à Insulina/genética , Ilhotas Pancreáticas/metabolismo , Neoplasias/metabolismo , Neoplasias/patologia , Ratos , Glutamato de Sódio/toxicidade
8.
Phytopathology ; 101(8): 923-8, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21425929

RESUMO

Heterokaryosis is an important mechanism which provides genetic variability increase in filamentous fungi. In order to assess the diversity of vegetative compatibility reactions existing among Colletotrichum acutatum isolates derived from different hosts, complementary nit mutants of each isolate were obtained and paired in all possible combinations. Vegetative compatibility groups (VCG) were identified among the isolates according to their ability to form viable heterokaryons. Seven VCGs were identified among the isolates, one of which contained isolates from different hosts. VCGs 2 and 6 contained two and three members, respectively; VCG-3 contained four members, and four VCGs (1, 4, 5, and 7) contained a single one. This study shows, for the first time, the isolation and the parasexual segregation of a heterozygous diploid sector derived from the heterokaryon formed with nit mutants from VCG-6. Diploid, named DE-3, showed nit+ phenotype and growth rate similar to the parental wild isolate. When inoculated in the presence of the haploidizing agent benomyl, the diploid strain produced parasexual haploid segregants exhibiting the nit phenotypes of the crossed mutants. Since viable heterokaryons and diploid may be formed among vegetative compatible isolates of C. acutatum, this study suggests that the parasexual cycle may be an alternative source of genetic variability in C. acutatum isolates.


Assuntos
Colletotrichum/classificação , Doenças das Plantas/microbiologia , Plantas/classificação , Plantas/microbiologia , Colletotrichum/genética , Colletotrichum/fisiologia , DNA Fúngico/genética , Diploide , Mutação , Reação em Cadeia da Polimerase , Especificidade da Espécie
9.
Phytother Res ; 23(2): 231-5, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18803228

RESUMO

The essential oil of Achillea millefolium is commonly used in folk medicine for the treatment of several diseases and has been demonstrated previously to exert an in vitro antimicrobial activity against human pathogens. Current study investigates the genotoxic activity of A. millefolium oil. The oil's major constituents are: chamazulene (42.15%), sabinene (19.72%), terpin-4-ol (5.22%), beta-caryophyllene (4.44%) and eucalyptol (3.10%), comprising 74.63% of the total. The oil's genotoxic evaluation was performed at concentrations of 0.13 microL/mL, 0.19 microL/mL and 0.25 microL/mL with a heterozygous diploid strain of Aspergillus nidulans, named A757//UT448, with green conidia. A statistically significant increasing number of yellow and white mitotic recombinants, per colony, of the diploid strain was reported after oil treatment with 0.19 microL/mL and 0.25 microL/mL concentrations. The genotoxicity of the oil was associated with the induction of mitotic non-disjunction or crossing-over by oil.


Assuntos
Achillea/química , Aspergillus nidulans/efeitos dos fármacos , Óleos Voláteis/farmacologia , Óleos de Plantas/farmacologia , Aspergillus nidulans/genética , Troca Genética/efeitos dos fármacos , Cromatografia Gasosa-Espectrometria de Massas , Medicina Tradicional , Testes de Mutagenicidade , Não Disjunção Genética/efeitos dos fármacos
10.
Rev Iberoam Micol ; 24(2): 167-70, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17604441

RESUMO

Isolates of Pyricularia grisea from wheat (Triticum aestivum Lam.) and triticale (x Triticosecale Wittmack) spikes with blast symptoms were analyzed by classical (VCG) and molecular (RAPD) techniques. P. grisea mutants, unable to use sodium nitrate (nit) as nitrogen source, were obtained with potassium chlorate. For vegetative compatibility (VCG) tests, genetically complementary nit mutant pairs were inoculated in a medium with sodium nitrate as a single nitrogen source. P. grisea isolates were divided into two vegetative compatibility groups and two RAPD groups. Since vegetative compatible strains may mutually exchange genetic and cytoplasmatic material, the contribution of the parasexual cycle in the genetic variability of Brazilian P. grisea isolates is discussed.


Assuntos
DNA Fúngico/genética , Grão Comestível/microbiologia , Magnaporthe/isolamento & purificação , Triticum/microbiologia , Brasil , Proteínas Fúngicas/genética , Proteínas Fúngicas/fisiologia , Genes Fúngicos , Teste de Complementação Genética , Variação Genética , Magnaporthe/genética , Magnaporthe/metabolismo , Magnaporthe/fisiologia , Nitratos/metabolismo , Nitrogênio/metabolismo , Doenças das Plantas/microbiologia , Técnica de Amplificação ao Acaso de DNA Polimórfico , Recombinação Genética
11.
Biol Res ; 35(3-4): 441-6, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12462996

RESUMO

The participation of the recently described uvsZ1 mutation in checkpoint control and the identification of epistatic relations between uvsZ1 mutation and uvsD153 and uvsJ1 mutations are provided. The effect of mutation uvsZ1 in mitotic exchanges into paba-bi (chromosome I) and cho-nic (chromosome VII) genetic intervals has also been evaluated. The mutation uvsZ1 was epistatic with regard to uvsD153 and uvsJ1 mutations, with no involvement with checkpoint control. In contrast to mutations in UvsB and UvsF groups, the uvsZ1 mutation failed to cause any changes in the frequencies of mitotic crossing-over. The distinct phenotypic traits given by mutation uvsZ1 suggest the presence of complex interactions among the different DNA repair pathways. Interaction may be an additional cell strategy of DNA damage response.


Assuntos
Aspergillus nidulans/genética , Epistasia Genética , Mutação/genética , Troca Genética , Dano ao DNA/genética , Reparo do DNA/genética , DNA Fúngico/genética , Genes Fúngicos , Tolerância a Radiação/genética , Raios Ultravioleta
12.
Biol Res ; 35(1): 31-8, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12125202

RESUMO

Vincristine is an alkaloid widely used as an antineoplastic agent. In eukaryotic cells the drug causes blockage in the G2 phase of the cell cycle and an increase in the frequency of sister chromatid exchanges. Due to the fact that germinating Aspergillus nidulans cells spend most of their cycle in G2 phase, they provide an excellent system for the study of mitotic crossing-over. Taking into account that mitotic crossing-over occurs during G2 period, the evaluation of recombinagenic and aneugenic potential of vincristine is provided with regard to two diploid strains of A. nidulans: a wild strain (uvsH+//uvsH+) and a defective one in DNA repair (uvsH//uvsH). Drug toxicity and its effect on the asexual cycle of A. nidulans has been evaluated as well. Treatment of both strains with vincristine did not change colony growth in the culture, however cytological analyses showed aberrant conidiophores. Recombinagenic potential of vincristine was evaluated by induction of gene homozygosis originally present in heterozygosity diploid strains (Homozygotization Index). Results show that vincristine induces mitotic crossing-over and higher frequency of aneuploid mitotic segregants. The results also show the recombinagenic and aneuploidogenic potential of vincristine and suggest its participation in the induction of secondary malignancies.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Aspergillus nidulans/efeitos dos fármacos , Troca Genética/efeitos dos fármacos , Diploide , Vincristina/farmacologia , Aneuploidia , Aspergillus nidulans/citologia , Aspergillus nidulans/genética , Divisão Celular/efeitos dos fármacos , Segregação de Cromossomos/efeitos dos fármacos , Genótipo , Mitose/efeitos dos fármacos , Troca de Cromátide Irmã/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...